DCM
LYRA

DAFNA Capital Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

DAFNA Capital Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,222
Closed -$1.48M – 77
2023
Q2 		$1.48M Buy
+7,222
New +$1M 0.41% 46

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

DAFNA Capital Management's LYRA Position: Q3 2023 in Review

DAFNA Capital Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2023, closing a stake of 7,222 shares — an estimated $1.48M sold.

DAFNA Capital Management first reported a position in LYRA in Q2 2023 and held it in 1 quarter. The position peaked at $1.48M in Q2 2023. 44 funds tracked by Wall St. Rank hold LYRA as of Q3 2023.

  • DAFNA Capital Management reported no remaining LYRA THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
  • DAFNA Capital Management sold 7,222 LYRA THERAPEUTICS INC shares in Q3 2023, an estimated $1.48M.
  • DAFNA Capital Management first reported a position in LYRA THERAPEUTICS INC in Q2 2023 and held it in 1 quarter.
  • DAFNA Capital Management's LYRA THERAPEUTICS INC position peaked at $1.48M in Q2 2023.
  • 44 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2023.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.